GlassScriptPhysician profile
Aiswaria George
NPI 1427693381
$994.59
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $120 · 2023: $545 · 2024: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $769 · Travel and Lodging: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $769.45 |
| Travel and Lodging | $104.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $242.15 | 2022-2023 | Bexsero |
| Daiichi Sankyo INC. | $111.11 | 2023-2024 | Vanflyta |
| Incyte Corporation | $110.40 | 2023-2024 | Jakafi |
| Abbott Laboratories | $104.85 | 2023 | Freestyle Libre 3 |
| Pharmaessentia USA Corporation | $82.58 | 2023-2024 | Besremi |
| Astellas Pharma US INC | $81.83 | 2023 | Cresemba, Xospata |
| Lilly USA, LLC | $79.34 | 2023-2024 | Jaypirca |
| Abbvie INC. | $49.17 | 2024 | |
| Taiho Oncology, INC. | $29.02 | 2023 | |
| Amgen INC. | $28.31 | 2023 | Blincyto |
| Rigel Pharmaceuticals, INC. | $26.57 | 2024 | Tavalisse, Rezlidhia |
| Servier Pharmaceuticals LLC | $24.98 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $24.28 | 2023 | Epkinly, Imbruvica |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aiswaria George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.